U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FORM PTO-1449

LIST OF REFERENCES CITED BY APPLICANT

ATTY. DOCKET: 17529(AP)	**SERIAL NO.: 10/680,879**
APPLICANT: Wheeler et al	**TITLE: METHODS FOR THE TREATMENT OF NEURODEGENERATION**
FILING DATE: October 7, 2003	**GROUP: 1617**

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	CA	6,627,210	9-2003	Olejnik et al			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, etc.)

	CB		Bartolini et al, "Aniracetam Restores Object Recognition Impaired by Age, Scopolamine, and Nucleus Basalis Lesions", Pharmacology Biochemistry and Behavior, Vol. 53, No. 2, pp. 277-283, 1996
	CC		Ogasawara et al, "Involvement of Cholinergic and GABAergic Systems in the Reversal of Memory Disruption by NS-105, a Cognition Enhancer", Pharmacology Biochemistry and Behavior, Vol. 64, No. 1, pp. 41-52, 1999
	CD		Chang et al, "Impaired and Spared Cholinergic Functions in the Hippocampus After Lesions of the Medial Septum/Vertical Limb of the Diagonal Band With 192 IgG-Saporin", HIPPOCAMPUS 14: 170-179 (2004)
	CE		McGaughy et al, "Sustained Attention Performance in Rats With Intracortical Infusions of 192 IgG-Saporin-Induced Cortical Cholinergic Deafferentation: Effects of Physotigmine and FG 7142", Behavioral Neuroscience, Vol. 112, No. 6, 1519-1525, 1998
	CF		Ramos et al, "Adrenergic Pharmacology and Cognition: Focus on the Prefrontal Cortex", Pharmacol Ther.; 113(3): 523-536, 2007 March
	CG		Avery et al, "The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Corex of Monkeys Performing a Spatial Working Memory Task", Neuropsychopharmacology, Vol. 23, No. 3, 2000
	CH		Franowicz et al, "Mutation of the α2A-Adrenoceptor Impairs Working Memory Performance and Annuls Cognitive Enhancement by Guanfacine", The Journal of Neuroscience, 22(19): 8771-8777, October 1, 2002
	CI		Friedman et al, "The Role of Norepinephrine in the Pathophysiology of Cognitive Disorders: Potential Applications to the Treatment of Cognitive Dysfunction in Schizophrenia and Alzheimer's Disease", Society of Biological Psychiatry, 1999
	CJ		Examiner D.R. Claytor, USPTO Office Action Date Mailed: 11/17/2006 and Response to this Office Action eFiled by Attorney Joel B. German on May 17, 2007 in Our Docket 17530, Serial No. 10/680,996)
	CK		Examiner D.R. Claytor, USPTO Office Action Date Mailed: July 26, 2007 and Response to this Office Action eFiled by Attorney Joel B. German on January 24, 2008 in Our Docket 17530, Serial No. 10/680,996)
	CL		Kedar, NP. Can we prevent Parkinson's and Alzheimer's disease? J Prostgrad Med 2003: 49:236-245 - **Cited by Examiner in Office Action Date Mailed July 26, 2007** in Our Docket 17530, Serial No. 10/680,996)
	CM		Walling, AD. Amyotrophic lateral sclerosis: Lou Gehrig's disease. Am Fam Phys. Vol. 59, No. 6, pages 1-11. **Cited by Examiner in Office Action Date Mailed July 26, 2007** in Our Docket 17530, Serial No. 10/680,996)
	CN		Polman et al. Drug treatment of multiple sclerosis. BMJ. Vol. 321, pgs. 490-494, 2000. **Cited by Examiner in Office Action Date Mailed July 26, 2007** in Our Docket 17530, Serial No. 10/680,996)

EXAMINER_____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.